Acrigen
Kensington, US · Founded 2019 · 2 known investors
Acrigen develops precision gene editing systems based on CRISPR, using novel αCas and μCas nuclease libraries paired with engineered anti-CRISPR (ErAcr) proteins to reduce off-target edits. The technology is aimed at human therapeutics for genetic diseases and is offered for licensing.
Founders & leadership
JB
Joseph Bondy-DenomyNamed on SEC filing
DR
David RabukaNamed on SEC filing
KB
Karen BoeziNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$775K disclosed across 1 round · 2019
▶$775KraisedJul 2019 · 9 investors · BiotechnologyRule 506(b)
▶$775KraisedJul 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph Bondy-DenomyDirector
- David RabukaExecutive Officer, Director, Promoter
- Karen BoeziDirector
- Offering amount
- $1M
- Amount sold
- $775K
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
IRIS MEDICINE4 shared keywordsIris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles. Its lead programs target repeat expansion disorders including Huntington's Disease, C9orf72 ALS, and the Spinocerebellar Ataxias.
Generate Biomedicines3 shared keywordsGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.
Estrigenix Therapeutics3 shared keywordsEstrigenix Therapeutics is a pharmaceutical company developing first-in-class therapeutics based on estrogen biology to treat and prevent hot flashes and dementia in post-menopausal women. It aims to license its lead compounds to pharmaceutical companies after phase 2 clinical trials, offering menopause symptom relief without the breast cancer and stroke risks of traditional hormone replacement therapy.
Precigen3 shared keywordsPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
Algen Biotechnologies3 shared keywordsAlgen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.
Companies competing with Acrigen for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2022 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $256.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $252.1K |
| National Science Foundation | Phase I | 2020 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Acrigen do?
- Acrigen develops precision gene editing systems based on CRISPR, using novel αCas and μCas nuclease libraries paired with engineered anti-CRISPR (ErAcr) proteins to reduce off-target edits. The technology is aimed at human therapeutics for genetic diseases and is offered for licensing.
- Who are Acrigen's investors?
- Acrigen's investors include Berkeley Catalyst, Dolby Family Ventures.
- How much funding has Acrigen raised?
- Acrigen has disclosed $775K raised across 1 round.
- Where is Acrigen headquartered?
- Acrigen is headquartered in Kensington, US.